Red blood cell membrane and platelet

Red blood cell (RBC) membranes and platelets are the primary cellular components involved in oxygen transport and hemostasis within the circulatory system (StatPearls, NBK534803; StatPearls, NBK545252). The RBC membrane is a complex lipid bilayer supported by a protein cytoskeleton that maintains cell shape and deformability, while platelets are cell fragments that utilize surface receptors like Glycoprotein IIb/IIIa for aggregation and clot formation (StatPearls, NBK545252). This composite 'target' is clinically significant in autoimmune conditions like Evans syndrome, where autoantibodies simultaneously target both cell types, leading to their destruction (StatPearls, NBK537129). Pharmacologically, drugs like pentoxifylline act on both components to improve blood flow by increasing RBC flexibility and reducing platelet aggregation (DrugBank, DB00806). Additionally, modern therapies targeting CD47 affect both cell types, as CD47 serves as a ubiquitous 'don't eat me' signal on their surfaces, and its inhibition can lead to treatment-induced anemia and thrombocytopenia (Nature Reviews Drug Discovery, 2020). Because this term encompasses multiple distinct cell types and molecular structures, it is generally considered a physiological system or a site of drug action rather than a single therapeutic molecular target.

Other names

Erythrocyte membrane and thrombocyteRBC and platelet surfacesBlood cell membranes

Drugs interact with these components by inhibiting specific surface receptors (e.g., P2Y12, GP IIb/IIIa), modulating membrane fluidity and deformability, or blocking 'don't eat me' signals like CD47 to regulate cell clearance and aggregation (DrugBank, DB00806; Nature Reviews Drug Discovery, 2020).